Banner - NPPA Connect
Logo Image
|Articles|April 15, 2013

FDA approves spray for plaque psoriasis

The Food and Drug Administration has approved a new drug application for Taro Pharmaceutical Industry’s Topicort (desoximetasone 0.25 percent) topical spray for the treatment of plaque psoriasis.

 

The Food and Drug Administration has approved a new drug application for Taro Pharmaceutical Industry’s Topicort (desoximetasone 0.25 percent) topical spray for the treatment of plaque psoriasis.

The corticosteroid is indicated for the treatment of plaque psoriasis in patients ages 18 and older. Annual sales for corticosteroid sprays in the United States total about $100 million, according to a news release. 

Related Content

Latest CME

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches
Video

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

View more
Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care
Video

Clear Skin, Clear Mind: Integrating Mental Health into Psoriasis Care

John Koo, MD; T.J. Chao, MPAS, PA-C

View more
Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes
Adaptive Learning

Medical Crossfire®: Navigating Chronic GVHD Prophylaxis and Treatment – Targeted Strategies to Elevate Patient Outcomes

Corey Cutler, MD, MPH, FRCP(C); Amin M. Alousi, MD; Mehdi Hamadani, MD; Anna Sureda, MD, PhD

View more